Agaimy Abbas, Daum Ondrej, Märkl Bruno, Lichtmannegger Ines, Michal Michal, Hartmann Arndt
*Institute of Pathology, University Hospital of Erlangen, Erlangen ‡Institute of Pathology, Klinikum Augsburg, Augsburg, Germany †Sikl's Department of Pathology, Charles University, Medical Faculty Hospital, Pilsen, Czech Republic.
Am J Surg Pathol. 2016 Apr;40(4):544-53. doi: 10.1097/PAS.0000000000000554.
Undifferentiated gastrointestinal tract carcinomas are rare highly aggressive neoplasms with frequent but not obligatory rhabdoid features. Recent studies showed loss of SMARCB1 (INI1), a core subunit of the SWI/SNF chromatin remodeling complex, in 50% of tested cases. However, the molecular pathways underlying histologically similar but SMARCB1-intact cases are unknown. We herein analyzed 13 cases for expression of 4 SWI/SNF complex subunits SMARCB1, SMARCA2, SMARCA4, and ARID1A and the mismatch-repair proteins MLH1, MSH2, MSH6, and PMS2 by immunohistochemistry. Patients included 12 men and 1 woman aged 32 to 81 years (median, 57 y). Site of origin was colon (5), small bowel (2), stomach (3), small+large intestine (1), small intestine+ampulla of Vater (1), and esophagogastric junction (1). All tumors showed anaplastic large to medium-sized cells with variable rhabdoid features, pleomorphic giant cells, and, rarely, spindle cell foci. Abortive gland formation was seen in 3 cases and bona fide glandular component in 1 case. Most cases strongly expressed vimentin and variably pancytokeratin. In total, 12/13 cases (92%) showed loss of at least 1 SWI/SNF component. Loss of SMARCB1 (5/13), SMARCA2 (10/13), SMARCA4 (2/13), and ARID1A (2/13) was observed either in combination or isolated. SMARCA2 loss was isolated in 5 cases and coexisted with lost SMARCB1 in 5 cases (all 5 SMARCB1-deficient tumors showed loss of SMARCA2 as well). Co-inactivation of SMARCB1 and SMARCA4 or of SMARCA2 and SMARCA4 was not observed. Two mismatch-repair-deficient cases (MLH1/PMS2) showed concurrent loss of SMARCB1, SMARCA2, and (one of them) ARID1A. This study illustrates for the first time loss of different components of the SWI/SNF complex other than SMARCB1 in undifferentiated gastrointestinal carcinomas including novel SMARCA4-deficient and SMARCA2-deficient cases. Our results underline the close link between SWI/SNF deficiency and the aggressive rhabdoid phenotype. Frequent loss of SMARCA2 possibly points to fragility/vulnerability of the SWI/SNF complex as a consequence of lost core subunit SMARCB1. The exact molecular mechanisms underlying co-inactivation of different SWI/SNF subunits merit further investigations.
未分化胃肠道癌是罕见的高侵袭性肿瘤,常具有横纹肌样特征,但并非必然如此。最近的研究显示,在50%的检测病例中,SWI/SNF染色质重塑复合体的核心亚基SMARCB1(INI1)缺失。然而,组织学上相似但SMARCB1完整的病例所涉及的分子途径尚不清楚。我们在此通过免疫组织化学分析了13例病例中4种SWI/SNF复合体亚基SMARCB1、SMARCA2、SMARCA4和ARID1A以及错配修复蛋白MLH1、MSH2、MSH6和PMS2的表达情况。患者包括12名男性和1名女性,年龄在32至81岁之间(中位数为57岁)。肿瘤原发部位为结肠(5例)、小肠(2例)、胃(3例)、小肠+大肠(1例)、小肠+ Vater壶腹(1例)和食管胃交界(1例)。所有肿瘤均显示出间变性大到中等大小的细胞,具有可变的横纹肌样特征、多形性巨细胞,很少有梭形细胞灶。3例可见不成熟的腺体形成,1例有真正的腺性成分。大多数病例强烈表达波形蛋白,细胞角蛋白表达各异。总体而言,13例中有12例(92%)显示至少1种SWI/SNF成分缺失。观察到SMARCB1(5/13)、SMARCA2(10/13)、SMARCA4(2/13)和ARID1A(2/13)的缺失,这些缺失可能单独出现或同时存在。SMARCA2缺失单独出现5例,与SMARCB1缺失同时存在5例(所有5例SMARCB1缺陷型肿瘤也显示SMARCA2缺失)。未观察到SMARCB1和SMARCA4或SMARCA2和SMARCA4的共同失活。2例错配修复缺陷病例(MLH1/PMS2)显示SMARCB1、SMARCA2和(其中1例)ARID1A同时缺失。本研究首次阐明了在未分化胃肠道癌中除SMARCB1外SWI/SNF复合体不同成分的缺失情况,包括新发现的SMARCA4缺陷型和SMARCA2缺陷型病例。我们的结果强调了SWI/SNF缺陷与侵袭性横纹肌样表型之间的密切联系。SMARCA2的频繁缺失可能表明由于核心亚基SMARCB1缺失导致SWI/SNF复合体的脆弱性。不同SWI/SNF亚基共同失活的具体分子机制值得进一步研究。